Skip to main content
SpringerLink
Log in

Neutralization of HIV by Antibodies

  • Protocol
  • First Online:
Therapeutic Antibodies

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 525))

Abstract

Antibodies can neutralize HIV-1 with potency and cross-reactivity that varies widely and is related but not correlated to their antigen-binding affinity. Therefore, in addition to measuring binding affinity, an evaluation of the antibody neutralizing activity in tissue cultures is important for development of antibody-based therapeutics, design of candidate vaccine immunogens, and understanding the mechanisms of virus entry, neutralization, and evasion of immune responses. The development of a standardized assay for measurement of the in vitro neutralizing activities of the antibody has remained a challenging goal in the last two decades. There are two types of widely used assays, which vary in details between different laboratories – assays based on cell line/pseudovirus and assays based on infection of peripheral blood mononuclear cells (PBMCs). Here we describe in detail the PBMC-based assay, which is more laborious but in our opinion represents a closer approximation of the in vivo situation. As with all other in vitro assays the results of such measurements are only an indication of the antibody potency in vivo, and animal studies and ultimately clinical trials are needed for the development of such antibodies as potential prophylactics and therapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251–260.

    Article  PubMed  CAS  Google Scholar 

  2. Shafer, R. W., Smeaton, L. M., Robbins, G. K., De Gruttola, V., Snyder, S. W., D'Aquila, R. T., et al. (2003) Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349, 2304–2315.

    Article  PubMed  CAS  Google Scholar 

  3. Robbins, G. K., De Gruttola, V., Shafer, R. W., Smeaton, L. M., Snyder, S. W., Pettinelli, C., et al. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349, 2293–2303.

    Article  PubMed  CAS  Google Scholar 

  4. Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., et al. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353, 863–868.

    Article  PubMed  CAS  Google Scholar 

  5. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853–860.

    Article  PubMed  Google Scholar 

  6. Fellay, J., Boubaker, K., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., et al. (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358, 1322–1327.

    Article  PubMed  CAS  Google Scholar 

  7. Friis-Moller, N., Sabin, C. A., Weber, R., d'Arminio Monforte, A., El-Sadr, W. M., Reiss, P., et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993–2003.

    Article  PubMed  Google Scholar 

  8. Friis-Moller, N., Weber, R., Reiss, P., Thiebaut, R., Kirk, O., d’Arminio Monforte, A., et al. (2003) Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179–1193.

    Article  PubMed  Google Scholar 

  9. Hirsch, M. S., Brun-Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D'Aquila, R. T., et al. (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37, 113–128.

    Article  PubMed  Google Scholar 

  10. Hirsch, M. S., Brun-Vezinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., et al. (2000) Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society – USA Panel. JAMA 283, 2417–2426.

    Article  PubMed  CAS  Google Scholar 

  11. Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vezinet, F., Clotet, B., et al. (1998) Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society – USA Panel. JAMA 279, 1984–1991.

    Article  PubMed  CAS  Google Scholar 

  12. Wit, F. W., van Leeuwen, R., Weverling, G. J., Jurriaans, S., Nauta, K., Steingrover, R., et al. (1999) Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 179, 790–798.

    Article  PubMed  CAS  Google Scholar 

  13. Katsnelson, A. (2006) Biotech jostles with pharma for slice of HIV market. Nat. Biotechnol. 24, 3–4.

    Article  PubMed  CAS  Google Scholar 

  14. McClure, M. O., Sattentau, Q. J., Beverley, P. C., Hearn, J. P., Fitzgerald, A. K., Zuckerman, A. J., et al. (1987) HIV infection of primate lymphocytes and conservation of the CD4 receptor. Nature 330, 487–489.

    Article  PubMed  CAS  Google Scholar 

  15. Sattentau, Q. J. (1992) CD4 activation of HIV fusion. Int. J. Cell Cloning 10, 323–332.

    Article  PubMed  CAS  Google Scholar 

  16. Sattentau, Q. J., and Moore, J. P. (1993) The role of CD4 in HIV binding and entry. Philos. Trans. R Soc. Lond. B Biol. Sci. 342, 59–66.

    Article  PubMed  CAS  Google Scholar 

  17. Broder, C. C., and Collman, R. G. (1997) Chemokine receptors and HIV. J. Leukoc. Biol. 62, 20–29.

    PubMed  CAS  Google Scholar 

  18. Clapham, P. R., and McKnight, A. (2001) HIV-1 receptors and cell tropism. Br. Med. Bull. 58, 43–59.

    Article  PubMed  CAS  Google Scholar 

  19. Dimitrov, A. S., Xiao, X., Dimitrov, D. S., and Blumenthal, R. (2001) Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J. Biol. Chem. 276, 30335–30341.

    Article  PubMed  CAS  Google Scholar 

  20. Gallo, S. A., Finnegan, C. M., Viard, M., Raviv, Y., Dimitrov, A., Rawat, S. S., et al. (2003) The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614, 36–50.

    Article  PubMed  CAS  Google Scholar 

  21. Pierson, T. C., and Doms, R. W. (2003) HIV-1 entry and its inhibition. Curr. Top. Microbiol. Immunol. 281, 1–27.

    PubMed  CAS  Google Scholar 

  22. Dimitrov, A. S., Louis, J. M., Bewley, C. A., Clore, G. M., and Blumenthal, R. (2005) Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 44, 12471–12479.

    Article  PubMed  CAS  Google Scholar 

  23. Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M. D., and Kaveri, S. V. (2004) Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol. Sci. 25, 306–310.

    Article  PubMed  CAS  Google Scholar 

  24. Dezube, B. J., Proper, J., Zhang, J., Choy, V. J., Weeden, W., Morrissey, J., et al. (2003) A passive immunotherapy, (PE) HRG214, in patients infected with human immunodeficiency virus: a phase I study. J. Infect. Dis. 187, 500–503.

    Article  PubMed  CAS  Google Scholar 

  25. Rusert, P., Kuster, H., Joos, B., Misselwitz, B., Gujer, C., Leemann, C., et al. (2005) Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J. Virol. 79, 8454–8469.

    Article  PubMed  CAS  Google Scholar 

  26. Choudhry, V., Zhang, M. Y., Dimitrova, D., Prabakaran, P., Dimitrov, A. S., Fouts, T. R., et al. (2006) Antibody-based inhibitors of HIV infection. Expert Opin. Biol. Ther. 6, 523–531.

    Article  PubMed  CAS  Google Scholar 

  27. Mc Cann, C. M., Song, R. J., and Ruprecht, R. M. (2005) Antibodies: can they protect against HIV infection? Curr. Drug Targets Infect. Disord. 5, 95–111.

    Article  PubMed  CAS  Google Scholar 

  28. Wolfe, E. J., Cavacini, L. A., Samore, M. H., Posner, M. R., Kozial, C., Spino, C., et al. (1996) Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Clin. Pharmacol. Ther. 59, 662–667.

    Article  PubMed  CAS  Google Scholar 

  29. Cavacini, L. A., Samore, M. H., Gambertoglio, J., Jackson, B., Duval, M., Wisnewski, A., et al. (1998) Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 14, 545–550.

    Article  PubMed  CAS  Google Scholar 

  30. Armbruster, C., Stiegler, G. M., Vcelar, B. A., Jager, W., Koller, U., Jilch, R., et al. (2004) Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother. 54, 915–920.

    Article  PubMed  CAS  Google Scholar 

  31. Armbruster, C., Stiegler, G. M., Vcelar, B. A., Jager, W., Michael, N. L., Vetter, N., et al. (2002) A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16, 227–233.

    Article  PubMed  CAS  Google Scholar 

  32. Dimitrov, A. (2007) Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Curr. Opin. Investig. Drugs 8, 653–661.

    PubMed  CAS  Google Scholar 

  33. Trkola, A., Ketas, T. J., Nagashima, K. A., Zhao, L., Cilliers, T., Morris, L., et al. (2001) Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75, 579–588.

    Article  PubMed  CAS  Google Scholar 

  34. No authors listed (2008) Phase 2 clinical trials started on PRO 140. AIDS Patient Care STDS 22, 159–160.

    Article  Google Scholar 

  35. Moulard, M., Phogat, S. K., Shu, Y., Labrijn, A. F., Xiao, X., Binley, J. M., et al. (2002) Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120–CD4–CCR5 complexes. Proc. Natl. Acad. Sci. USA 99, 6913–6918.

    Article  PubMed  CAS  Google Scholar 

  36. Zhang, M. Y., Shu, Y., Phogat, S., Xiao, X., Cham, F., Bouma, P., et al. (2003) Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J. Immunol. Methods 283, 17–25.

    Article  PubMed  CAS  Google Scholar 

  37. Zhang, M. Y., Shu, Y., Rudolph, D., Prabakaran, P., Labrijn, A. F., Zwick, M. B., et al. (2004) Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J. Mol. Biol. 335, 209–219.

    Article  PubMed  CAS  Google Scholar 

  38. Zhang, M. Y., Xiao, X., Sidorov, I. A., Choudhry, V., Cham, F., Zhang, P. F., et al. (2004) Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J. Virol. 78, 9233–9242.

    Article  PubMed  CAS  Google Scholar 

  39. Zhang, M. Y., and Dimitrov, D. S. (2007) Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr. Pharm. Des. 13, 203–212.

    Article  PubMed  CAS  Google Scholar 

  40. Polonis, V. R., Brown, B. K., Borges, A. R., Zolla-Pazner, S., Dimitrov, D. S., Zhang, M. Y., et al. (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375, 315–320.

    Article  PubMed  CAS  Google Scholar 

  41. Brown, B. K., Wieczorek, L., Sanders-Buell, E., Borges, A. R., Robb, M. L., Birx, D. L., et al. (2008) Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375, 529–538.

    Article  PubMed  CAS  Google Scholar 

  42. Choudhry, V., Zhang, M. Y., Harris, I., Sidorov, I. A., Vu, B., Dimitrov, A. S., et al. (2006) Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem. Biophys. Res. Commun. 348, 1107–1115.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Profectus BioSciences, Inc., Baltimore, MD, USA

    Ilia Prado, Timothy R. Fouts & Antony S. Dimitrov

Authors
  1. Ilia Prado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy R. Fouts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antony S. Dimitrov
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Humana Press, a part of Springer Science+Business Media, LLC

    About this protocol

    Cite this protocol

    Prado, I., Fouts, T.R., Dimitrov, A.S. (2009). Neutralization of HIV by Antibodies. In: Dimitrov, A. (eds) Therapeutic Antibodies. Methods in Molecular Biology™, vol 525. Humana Press. https://doi.org/10.1007/978-1-59745-554-1_28

    Download citation

    • DOI: https://doi.org/10.1007/978-1-59745-554-1_28

    • Published:

    • Publisher Name: Humana Press

    • Print ISBN: 978-1-934115-92-3

    • Online ISBN: 978-1-59745-554-1

    • eBook Packages: Springer Protocols

    Publish with us

    Policies and ethics

    Search

    Navigation